Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the dual GIP/GLP-1 receptor agonist tirzepatide may provide adjunctive benefits to insulin therapy in type 1 diabetes.
- GLP-1RAs and tirzepatide are being evaluated for their effects on individuals with type 1 diabetes who also have overweight or obesity.
- There is a focus on the benefit-risk balance associated with these treatments.
- The evolving evidence suggests potential advantages in managing blood sugar levels.
- Safety and efficacy outcomes remain a critical consideration for these adjunct therapies.
Simplified